Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

JP Morgan reported in their recent outlook piece that "The backdrop for the European consumer is also improving. Real wages ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

New York City’s housing shortage may find an unlikely hero in its glut of underused office buildings, according to Brad ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Key Points Pfizer stands as one of the largest pharmaceutical companies in the world.Although it has an attractive 7.1% yield, it has a big blemish in its dividend past.Investors looking at drug ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Okay, well, I have not been recommending, my stock in the pharma business is Lilly, and the med equipment is Abbott. I do ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Pfizer (PFE) stock in focus as Sally Susman, the company's Chief Corporate Affairs Officer, plans to depart after 18 years. Read more here.